Articles

Deep Dives

Articles that either helped my imposter syndrome or confirmed it was justified all along.

StonesEvidenceEndourology May 2026

Suction URS: The CVAC System and Why Residual Fragments Matter

The ASPIRE trial showed a 73% reduction in healthcare events at two years with suction ureteroscopy. Here is what the evidence actually says, and what it doesn't.

OncologyEvidenceGuidelines May 2026

When the Data Don't Fit the Dogma: Five Trials That Changed How We Think

ProtecT, PIVOT, CARMENA, SWOG 8710, POUT. Five trials that made urologists uncomfortable. Here is what they actually changed, and what they didn't.

AndrologyEvidenceSafety May 2026

Finasteride 1mg and New-Onset ED: The 3-Year Signal We Couldn't See Before

A propensity-matched cohort of over 10,000 young men links finasteride 1mg to new-onset erectile dysfunction at three years. The longest follow-up signal we've seen for this question.

StonesEvidenceEndourology May 2026

Do You Actually Need That Foley After URS?

A 2025 EULIS-YAU RCT tested routine Foley placement after flexible ureteroscopy and JJ stent insertion. The short answer: not really.

OncologyEvidenceEndourology May 2026

Histotripsy for Kidney Tumours: No Scalpel, No Needle, No Heat

HistoSonics has submitted the Edison Histotripsy System to the FDA for kidney tumour destruction. Here is what the technology actually does, what the evidence says, and what we don't know yet.

OncologyAndrologyEvidence May 2026

Low Testosterone at Prostate Cancer Diagnosis: Not the Free Pass We Thought

Two 2025 studies suggest low testosterone at diagnosis independently predicts worse survival in prostate cancer. The effect sizes are hard to ignore.

AndrologyEvidencePeyronie's April 2026

A Multimodal Approach to Peyronie's

A new perspective article in IJIR proposes the first fully specified multimodal protocol for Peyronie's disease. The rationale is genuinely interesting. The evidence is still early.

BPHEvidenceGuidelines April 2026

Second-Wave BPH Devices: Useful Signal, Thin Evidence

Optilume, Zenflow, Butterfly, ProVee, Urocross, FloStent - a new wave of LIST and FIT devices is arriving with compelling narratives. Here is how to read them before the hype sets in.

StonesGuidelinesOn-call March 2026

CIRFs Are Dead: Stop Using That Term on the Ward Round

The AUA 2026 Surgical Stone Guidelines have quietly retired one of the most commonly used phrases in post-op urology. Here is what changed, why it matters, and what to say instead.

StonesEvidenceGuidelines February 2026

Beyond Hydration: What the PUSH Trial Tells Us About Stone Recurrence in 2026

The PUSH trial increased urine volume in stone formers and still failed to reduce stone recurrence. Here is what that means for the way we counsel patients.

Surgical PerformanceTrainingOn-call February 2026

The Quiet Eye: What Elite Performers Know About Focus That Most Surgeons Don't

There is a measurable moment of stillness between locking onto your target and initiating movement. Elite performers have more of it. Here is what that means for surgical training.

AppResource January 2026

Inside the UroRef App

A walkthrough of what UroRef actually contains - procedures, emergency decision trees, drug doses, calculators, clinic frameworks and BAUS patient leaflets. All in one place, offline.

PersonalBackground January 2026

Why I Built UroRef

UroRef was not built by someone pretending medicine is simple. It was built by someone who remembers very clearly what it feels like when your brain goes blank at exactly the wrong moment.